Navigation Links
UC Davis bench-to-bedside research: Promising treatment in clinical trials
Date:3/26/2009

properties of the s-EH inhibitors to the stage where we could present a convincing picture to venture groups of compounds ready to move to the clinic."

In 2005, the company raised more than $51 million in Series A financing led by Frazier Healthcare Ventures, Alta Partners, Three Arch Partners, Burrill & Company and Altitude Life Science Ventures.

Today, the biotech company, based in Hayward, is dedicated to the discovery and development of novel drugs to treat type 2 diabetes, hypertension and inflammatory disorders, Hammock said. It is billed as the "world's leading company focused on s-EH, an important enzyme for the metabolism of arachidonic acid that plays an essential role in metabolic, inflammatory and cardiovascular physiology."

"Our main goal," Hammock said, "was to set up a system of a science-driven company where we reduce the cost of drug registration by using very good incisive science. We also want to reward and motivate the people who do the work; provide a funding and training environment to help teach students and postgraduates to write proposals; and allow scientists to move between an academic and industrial environment in the early stage to help determine career directions."

Another goal: a low-cost, affordable drug. "The sickest people in the world, of course, cannot pay for the drugs they need," Hammock said. "The chemistry developed around the s-EH inhibitors allows us to make powerful but inexpensive drugs that could be produced in developing countries."

Meanwhile, the clinical trials under way represent two firsts, said James Sabry, president and chief executive officer of Arte Therapeutics. "This is the first clinical study of a s-EH inhibitor in patients, and the first study designed to establish proof of concept that s-EH inhibition modulates glucose metabolism or blood pressure in patients with impaired glucose tolerance and hypertension."

."AR9281 has demonstrated an excellent
'/>"/>

Contact: Kathy Keatley Garvey
kegarvey@ucdavis.edu
530-754-6894
University of California - Davis
Source:Eurekalert  

Page: 1 2 3 4 5

Related biology news :

1. UC Davis research shows that newly discovered drug reduces heart enlargement
2. UC Davis researchers find molecule that targets brain tumors
3. UC Davis discovery offers hope for treating kidney cancer
4. UC Davis team refines cancer treatments to reduce potential nerve damage
5. UC Davis researchers exploring gene therapy to fight AIDS
6. UC Davis researchers discover Achilles heel in pancreatic cancer
7. UC Davis researchers discover a key to aggressive breast cancer
8. UC Davis chemical ecologist wins major award
9. UC Davis researchers discover new drug target for inflammatory disease
10. UC Davis researchers define characteristics, treatment options for XXYY syndrome
11. UC Davis researcher leads climate-change discovery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UC Davis bench-to-bedside research: Promising treatment in clinical trials
(Date:10/29/2014)... research presented at the Society for Integrative Oncology ... for the first time that it is possible ... readily available nutritional supplement, AHCC. ... Smith, Pharm.D., associate professor in the Department of ... of Texas Health Science Center at Houston (UTHealth) ...
(Date:10/29/2014)... overwhelming number of chemicals from household and industrial products ... our bodies. But for most of them, scientists have ... they,ve taken the first step toward doing that by ... Their new method is published in the ACS journal ... Wambaugh and colleagues note that the risks to human ...
(Date:10/29/2014)... in German . ... and Peter Schlögelhofer at the Max F. Perutz Laboratories ... University of Vienna dived into the process of meiosis ... display an inversion of the standard meiotic phases. The ... Nature Communications . , Meiosis is the two-step ...
Breaking Biology News(10 mins):HPV infections in women eradicated by AHCC, Japanese mushroom extract 2Meiotic cell division 'the other way round' 2
... Molecular Imaging Labs (MI Labs) have succeeded in combining ... of equipment. These techniques are particularly useful for cancer ... microSPECT. SPECT and PET can be performed simultaneously and ... microPET. The new device is known as the VECTor ...
... Properties SA announces the winners of the Reaxys PhD ... PhD or having completed a PhD within the last ... the fields of organic, organometallic and inorganic chemistry. ... launched in January 2010. Submissions consisted of a representative ...
... Navarra, the Polytechnic University of Madrid (CBGP), the University ... Institute of Agricultural Research have managed to sequence the ... olive tree. The study, included in the June issue ... of the genome of a pathogenic bacteria undertaken in ...
Cached Biology News:TU Delft and MI Labs merge PET and SPECT biomedical imaging techniques and increase resolution 2The Reaxys Ph.D. Prize awards innovative research in organic, organometallic and inorganic chemistry 2The Reaxys Ph.D. Prize awards innovative research in organic, organometallic and inorganic chemistry 3Genome of bacteria responsible for tuberculosis of olive tree sequenced 2
(Date:10/31/2014)... Jeffrey T. Manuel, assistant professor in Southern Illinois ... of Arts and Sciences, is teaming up with the ... fuels in Illinois. , “Farmers, researchers, business ... build Illinois’ biofuels industry for decades,” Manuel said. “This ... agricultural and business history. , “Fuel alcohol has ...
(Date:10/31/2014)... The report "Dairy Alternative (Beverage) Market ... Sweetened, Unsweetened), Channel (Supermarket, Health Store, Pharmacy, Convenience ... to 2018," defines and segments the dairy alternative ... revenue and volume for plant-based dairy alternative beverages. ... $14 Billion by 2018 with the Asia-Pacific region ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 Stronger ... healthcare, construction, finance and consumer electronics will help ... reason, industry research firm IBISWorld has added a ... its growing industry report collection. , The Biometrics ... for biometric technologies such as fingerprint, iris, retina ...
(Date:10/30/2014)... 30, 2014 The report “Fragrance Ingredients ... Application (Cosmetics & Toiletries, and Soaps & Detergents) & ... has defined and segmented the Fragrance Ingredients Market with ... terms of value. The market has been segmented on ... Europe, Asia-Pacific, Latin America, and Rest of the World ...
Breaking Biology Technology:SIUE History Prof Manuel Working on Biofuels Book with NCERC 2SIUE History Prof Manuel Working on Biofuels Book with NCERC 3Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 3Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 4Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 2Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 3Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 2Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 3Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 4Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 5
... , , , SUNNYVALE, ... leader in the field of radiosurgery, announced today that its management is scheduled ... City on Thursday, September 10, 2009 at 11:00 a.m. ET (8:00 a.m. PT). ... available online from the investor relations page of the Company,s Web site at ...
... ... its national print advertising campaign for Cobroxin, the first clinically proven, over-the-counter treatment for ... will run in Arthritis Today, Prevention, Health, Star, Woman,s World, Soap Opera, and Self ... (Vocus) ...
... , CAMBRIDGE, Mass., Sept. 3 Idenix ... management will present a corporate overview at the upcoming Thomas ... at 10:55 a.m. ET at the Four Seasons Hotel in ... Conference on Monday, September( )14, 2009 at 3:55 p.m. ET ...
Cached Biology Technology:Accuray Incorporated to Present at Robert Baird 2009 Healthcare Conference 2Nutra Pharmaceutical's U.S. distributor, XenaCare Holdings Announces National Print Advertising Campaign for Cobroxin, a Treatment for Moderate to Severe (Stage 2) Pain 2
...
Fetal Calf Serum Replacement (Bistec) serum...
NEWBORN CALF SERUM AND PLASMA...
... phase reagent for Virus ... & unique water insoluble ... detergents and chaotropes; Engineered ... non-envelop viruses while preserving ...
Biology Products: